Paul B. Eckburg, MD

Consultant
Spero Therapeutics

Disclosure: AN2 Therapeutics (Consultant)Bugworks Research (Advisor or Review Panel member)Curza (Advisor or Review Panel member)Paratek Pharmaceuticals (Advisor or Review Panel member)SNIPR Biome (Consultant)

Presentation(s):

• LB-3 - Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study

  Saturday, October 24, 2020
  10:10am – 10:20am EDT